This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

David Sobek

Contributor

Sobek writes on biotech, with a focus on small-cap oncology and antibiotics companies. He received a PhD in political science from Penn State in 2003. He is the proprietor of Sobek Analytics.


David Sobek
By This Author:
« Back
Page 1 of 6

Safety Worries Over Celgene's Experimental Crohn's Drug Overblown

By David Sobek

The first public presentation of the GED-031 phase II data will be on Oct. 21 at a European medical conference.

08:26AM 09/17/14

Trade Ebola Stocks? Sure, But Don't Bet on Big Business Opportunity

By David Sobek

The Ebola outbreak in West Africa is a public health emergency which has also captured the attention of U.S. investors (perhaps I should say traders.)

09:36AM 09/10/14

Tetraphase Oral Antibiotic Data Look Good

By David Sobek

Tetraphase is on track to begin second portion of pivotal study in the fourth quarter.

06:30AM 09/03/14

Previewing Tetraphase Oral Antibiotic Study Results

By David Sobek

Tetraphase will report data from a phase III study of eravacycline in which the experimental antibiotic is first given by intravenous infusion and then transitioned to an oral form.

08:00AM 08/27/14

Epizyme First Look at Blood Cancer Drug Encourages

By David Sobek

Epizyme's technology platform focuses on developing drugs to regulate a class of cancer-causing enzymes.

08:59AM 08/21/14

Pharmacyclics Has Edge Over Blood Cancer Competitors

By David Sobek

Imbruvica will be an important part of the treatment landscape for blood cancers.

10:49AM 08/13/14

Biotech Valuations Are Low Not Stretched. Here's Why.

By David Sobek

If biotech companies can assuage concerns about long-term growth, multiples might expand.

08:35AM 07/31/14

Seattle Genetics Nearing Key Test for Investor Confidence

By David Sobek

The Seattle Genetics' bull thesis will be tested when results are announced from the "AETHERA" study of Adcetris in post-stem cell transplant Hodgkin's lymphoma patients.

09:03AM 07/16/14

Grading Sobek's Mid-Year Biotech Stock Predictions

By David Sobek

The year is halfway over, so it's a good time to look back and give mid-term grades on my fearless 2014 predictions.

10:14AM 07/09/14

Closer Look at Gilead's Slowing Hep C Prescriptions

By David Sobek

Is a slowdown in Sovaldi prescriptions the beginning of the highly anticipated "re-warehousing" of patients, or is some other factor at play?

10:23AM 06/26/14

« Back
Page 1 of 6

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 17,279.74 +13.75 0.08%
S&P 500 2,010.40 -0.96 -0.05%
NASDAQ 4,579.7870 -13.6380 -0.30%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs